FDA opens Office of Innovation and Clinical Trial Modernization within CDER, with Marie Bradley as acting director of the Division of Real-World Evidence Analytics.

Found in 70 percent of cancers, the gene is seen as a grand orchestrator but has been surprisingly difficult to stop.

Juan Andres will come out of retirement to rejoin Moderna as COO on Oct. 5, bringing his intimate knowledge of the company as its Merck-partnered cancer vaccine gathers momentum in the clinic.

With prospects for new treatments at an all-time high, researchers are looking for ways to boost survival by treating the disease early.

The companies were exploring the experimental medicine FHD-909 for advanced and metastatic solid tumors. But Foghorn said the partners will not make it to the dose-expansion phase of the study.

Intended to help with biosecurity, it works with a popular AI protein design tool.

Just months after trimming jobs in New Jersey following an acquisition, BioMarin is laying off 117 employees in California as part of a consolidation of its footprint. | Just months after trimming job...

Researchers are asking why patients, like former Senator Ben Sasse, inevitably develop resistance to the drug daraxonrasib.

Targeted gene therapies are highly effective at stopping cancers, but the very abundance of the treatments, plus cost and sluggish change, are hindering access.

BioNTech is set to shutter multiple sites in Germany, impacting about 1,800 jobs, after efforts to find buyers fell through. | BioNTech is set to shutter several sites in Germany, impacting about 1,80...

In the deal with SciBrunch, Merck gained worldwide exclusive rights to the KRAS G12D inhibitor SPR2015.

'The inefficiency is kind of the magic of it': How a UCSF scientist's persistence led to Revolution Medicines' groundbreaking pancreatic cancer drug and a $1 million prize.

A brand-new biotech startup with thousands of AI agents is sprouting at Stanford.

Readers respond to a guest essay about the costs and delays in getting experimental treatments to patients.

Bay Area companies have scored 14 drug approvals from the FDA this year. Find out who got the latest one.

AI-predicted protein complex structures for more than 2,800 viruses are now openly available in the AlphaFold Database. To better understand and protect against emerging pathogens, the dataset priorit...

In the 1950s and 1960s, doctors gave the drug thalidomide to pregnant patients without telling them — and without FDA approval. Now those patients' children want recognition.

ADARx is the only maker of RNA-based drugs to go public since 2024 and the first RNAi biotech to price an IPO in the U.S. in more than a decade.

Humans are evolving faster through culture than through biology.

Endpoints 11 winner: Weihao Xu built Kali Therapeutics with $18M, no lab and Chinese vendors — then sold its lead T cell engager to Sanofi for $180M upfront.

Mount Sinai researchers have identified how APOE4, the strongest genetic risk factor for Alzheimer's disease, damages the brain's blood vessels and promotes the buildup of abnormal proteins linked to ...

A joint team of researchers at Bar-Ilan University and the Weizmann Institute has used advanced computational design methods to enhance the ability of genetically engineered immune cells to recognize ...

Lilly taps Beijing's InnoCare to discover drugs against up to five targets in a deal worth up to $3.35B, with up to $100M upfront and near-term.

Kyverna's CAR-T miv-cel showed a 49% median mobility gain at one year in stiff person syndrome, with no IEC-HS cases.

Here's how this AI-focused company — one of the first with a biotech drug in the clinic — plans to use its fresh $75M round

Stories of science funding being cut, labs shutting down and scientists losing jobs have flooded the media under Trump's administration. These six graphics show how those changes have affected U.S. bi...

The firm has raised $65 million in series A funding

Google left Pacific Shores behind. Now one of the Bay Area's fastest-growing biotech companies is poised to take it over in a major move.

One of the Bay Area's most storied biotech companies plans a massive new R&D center to kick off the reimagining of its Peninsula headquarters.

ALS is devastating. This startup thinks it's found a way to strike it out

A half-century ago, scientists and lawyers agreed to strict self-regulation in DNA research to avoid catastrophe. Can A.I. follow the same model?